1. Home
  2. LNTH vs PTGX Comparison

LNTH vs PTGX Comparison

Compare LNTH & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantheus Holdings Inc.

LNTH

Lantheus Holdings Inc.

HOLD

Current Price

$100.25

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

HOLD

Current Price

$95.41

Market Cap

6.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNTH
PTGX
Founded
1956
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
6.4B
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
LNTH
PTGX
Price
$100.25
$95.41
Analyst Decision
Buy
Strong Buy
Analyst Count
6
13
Target Price
$87.00
$108.23
AVG Volume (30 Days)
1.0M
469.1K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.80
0.05
Revenue
$343,374,000.00
N/A
Revenue This Year
N/A
$874.25
Revenue Next Year
$14.19
N/A
P/E Ratio
$53.50
$1,864.60
Revenue Growth
3.62
N/A
52 Week Low
$47.27
$49.86
52 Week High
$102.66
$107.84

Technical Indicators

Market Signals
Indicator
LNTH
PTGX
Relative Strength Index (RSI) 67.69 39.72
Support Level $91.65 $90.58
Resistance Level $102.66 $98.27
Average True Range (ATR) 3.42 3.75
MACD -0.10 -0.90
Stochastic Oscillator 86.60 8.17

Price Performance

Historical Comparison
LNTH
PTGX

About LNTH Lantheus Holdings Inc.

Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Share on Social Networks: